Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chadi Nabhan

Showing results (41-50 of 199) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the ModelChadi Nabhan, Anthony R Mato
Current Oncology Reports|August 7, 2002
Management of acute promyelocytic leukemiaMartin S Tallman, Chadi Nabhan
Hematology/Oncology Clinics of North America|March 12, 2003
Hereditary and acquired defects in the fibrinolytic system associated with thrombosisHau C Kwaan, Chadi Nabhan
Clinical Genitourinary Cancer|May 22, 2012
The role of IMiDs alone or in combination in prostate cancerChadi Nabhan, Daniel P Petrylak
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Behavioral Economics and the Future of BiosimilarsChadi Nabhan, Bruce A Feinberg
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R Mato
Seminars in Oncology|February 1, 2017
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemiaChadi Nabhan, Steven T Rosen
British Journal of Haematology|November 30, 2006
Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?Chadi Nabhan, Steven Coutré, Peter Hillmen
JAMA Oncology|July 4, 2019
Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017Marjorie Zettler, Ethan Basch, Chadi Nabhan
JAMA Oncology|May 17, 2019
Real-world Evidence-What Does It Really Mean?Chadi Nabhan, Andrew Klink, Vinay Prasad
Pageof 20

Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the ModelChadi Nabhan, Anthony R Mato
Current Oncology Reports|August 7, 2002
Management of acute promyelocytic leukemiaMartin S Tallman, Chadi Nabhan
Hematology/Oncology Clinics of North America|March 12, 2003
Hereditary and acquired defects in the fibrinolytic system associated with thrombosisHau C Kwaan, Chadi Nabhan
Clinical Genitourinary Cancer|May 22, 2012
The role of IMiDs alone or in combination in prostate cancerChadi Nabhan, Daniel P Petrylak
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Behavioral Economics and the Future of BiosimilarsChadi Nabhan, Bruce A Feinberg
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R Mato
Seminars in Oncology|February 1, 2017
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemiaChadi Nabhan, Steven T Rosen
British Journal of Haematology|November 30, 2006
Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?Chadi Nabhan, Steven Coutré, Peter Hillmen
JAMA Oncology|July 4, 2019
Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017Marjorie Zettler, Ethan Basch, Chadi Nabhan
JAMA Oncology|May 17, 2019
Real-world Evidence-What Does It Really Mean?Chadi Nabhan, Andrew Klink, Vinay Prasad
Pageof 20